Dicerna Pharmaceuticals Inc

NASDAQ:DRNA  
37.37
+3.81 (+11.35%)
Products, Strategic Combinations, Other Pre-Announcement

Dicerna Announces Boehringer Ingelheim’s Acceptance Of Candidate For Development Under RNAi Research Collaboration And License Agreement

Published: 05/24/2021 12:15 GMT
Dicerna Pharmaceuticals Inc (DRNA) - Dicerna Announces Boehringer Ingelheim’s Acceptance of Candidate for Development Under Rnai Research Collaboration and License Agreement.
Dicerna Pharmaceuticals Inc - Development Candidate Will Be Evaluated for Treatment of Nonalcoholic Steatohepatitis.
Dicerna Pharmaceuticals Inc - Candidate Selection Triggers Single-digit Multimillion USD Milestone Payment to Dicerna.
Dicerna Pharmaceuticals Inc - Expects to Receive Single-digit Multimillion USD Preclinical Milestone Payment in Q2 2021.
Dicerna Pharmaceuticals Inc - Under Agreement, Eligible to Receive Up to $170.0 Million in Potential Additional Development and Commercial Milestones.